Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byAmicus Therapeutics
Date11/2013

General Information

Websitecallidusbiopharma...
CategoryBioTech
Phone215-434-7482
Emailinfo@callidusbiop...
Employees
Founded2010

Offices

Doylestown, USA
3805 Old Easton Road
Doylestown, PA, 18902
USA

People

Founder & Chief Scientific Officer
President & CEO
Vice President, Analytics and Assay Development

Funding

TOTAL $6.21M
FUNDING TOTAL $6.21M
Seed, 7/2012
$1.61M
Series A, 5/2013
$4.6M

Tags

Callidus Biopharma

Callidus Biopharma is a drug discovery company focused on best-in-class enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Callidus’ novel technology platform is based on attaching a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body.

The company’s therapeutics offer the potential to significantly reduce the amount of drug that needs to be infused, which translates to patient and medical benefits of better efficacy, shorter infusion times, reduced immunogenicity, and greater convenience. Our lead program is for Pompe Disease but we are also applying our IGF2 technology to other LSDs to improve drug targeting and efficacy. We have also created a more stable enzyme which has the potential to be a superior ERT for Gaucher Disease.

Recent Milestones

Videos

Screenshots

Sources

  1. Amicus Therapeutics acquires Callidus Biopharma, announces financing (finance.yahoo.com) [edit]
  2. SEC (sec.gov) [edit]
  3. Callidus Biopharma Closes $4.6M Series A Financing (finsmes.com) [edit]
Edit This Page
Last Edited 2/17/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy